Evry, France, May 10, 2016 -- Global Bioenergies (Alternext Paris: ALGBE) announces that the performance obtained in 2015 at laboratory scale has now been successfully reproduced in the pilot unit installed in Pomacle-Bazancourt (eastern France).
During the last fermentation-trial series, up to 74% of commercial target yield has been achieved. In addition, a high yield (higher than 65% of target) was maintained over several days. Strong robustness of the process is a key parameter for exploitation at larger scale.
Global Bioenergies' Isobutene process is the first-of-a-kind technology to directly produce a gas by fermentation. These results factually demonstrate that the process scales up very well at this stage. The demo plant, presently under construction in Germany, will allow running the technology at ton scale within months.
Marc Delcourt, co-founder and CEO of Global Bioenergies, concludes: "While our technology comes closer to commercial performances, the oil market is now swinging back. Innovative solutions to produce fuels and materials are more necessary today than ever. Global Bioenergies is getting prepared to play an important role in the transition of the energy and chemistry worlds toward technologies more friendly to the environment."
About GLOBAL BIOENERGIES
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performances of its process, operates its industrial pilot, has begun the construction of its demo plant in Germany, and prepares the first full-scale plant through a Joint-Venture with Cristal Union, named IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 - ALGBE).
Should you like to be kept informed, subscribe to our news feed on
www.global-bioenergies.com
Follow us on Twitter: @GlobalBioenergi
Contact
GLOBAL BIOENERGIES
Thomas BUHL
Head of Business Development
Phone: +33 (0)1 64 98 20 50
Email: [email protected]
PRESS RELEASE http://hugin.info/166909/R/2011379/744620.pdf
HUG#2011379


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Instagram Outage Disrupts Thousands of U.S. Users
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 



